Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024

New data reinforces findings from MINDACT supporting MammaPrintยฎ in Read More

2024-12-11T15:26:18-05:00December 11th, 2024|Press Releases|

Agendia to Unveil New Findings in Early-Stage Breast Cancer at San Antonio Breast Cancer Symposium 2024

New data reinforces MammaPrintยฎ and BluePrintยฎ testsโ€™ expanding clinical Read More

2024-11-21T15:36:37-05:00November 25th, 2024|Press Releases|
Go to Top